Tumor necrosis factor-alpha alters pulmonary vasoreactivity via neutrophil-derived oxidants

Am J Physiol. 1993 Nov;265(5 Pt 1):L462-71. doi: 10.1152/ajplung.1993.265.5.L462.

Abstract

We postulated that tumor necrosis factor-alpha (TNF) "primes" the lung for the development of pulmonary vasoconstriction and edema by inducing the release of polymorphonuclear leukocyte (PMN)-derived reactive oxidant species (ROS). Guinea pigs were injected with TNF (1.6 x 10(5) U/kg ip), and the lungs isolated 18 h later. Compared with controls, TNF pretreatment resulted in 1) greater increases in lung weight and capillary pressure in response to the thromboxane A2 mimetic U-46619 (365 pmol/min) and 2) an increase in the dose of acetylcholine (ACh) causing 50% of maximal dilation (EC50). The vascular effects of TNF were associated with 1) decreased lung effluent nitrite (NO2-, oxidation product of nitric oxide), 2) increased lung effluent superoxide (O2-), and 3) increased lung myeloperoxidase (MPO). Superoxide dismutase (SOD, 10 U/ml) prevented 1) the effects of TNF on the hemodynamic responses to U-46619 and ACh and 2) the TNF-induced decrease in NO2-. The effects of TNF on lung MPO and effluent O2- were prevented using cyclophosphamide intraperitoneally (100 mg/kg 5 days before, and 50 mg/kg 1 day before, treatment with TNF or control). The data suggest that ROS generated from PMN mediate the decrease in nitric oxide and altered pulmonary vasoreactivity induced by TNF.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • Acetylcholine / pharmacology
  • Animals
  • Capillaries / drug effects
  • Capillaries / physiology
  • Guinea Pigs
  • Humans
  • In Vitro Techniques
  • Kinetics
  • Lung / drug effects
  • Lung / physiology*
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / physiology
  • Neutrophils / physiology*
  • Nitroprusside / pharmacology
  • Organ Size / drug effects
  • Oxidants / pharmacology*
  • Prostaglandin Endoperoxides, Synthetic / pharmacology
  • Pulmonary Artery / drug effects
  • Pulmonary Artery / physiology*
  • Pulmonary Circulation / drug effects
  • Pulmonary Circulation / physiology*
  • Pulmonary Veins / drug effects
  • Pulmonary Veins / physiology*
  • Recombinant Proteins / pharmacology
  • Superoxide Dismutase / pharmacology
  • Tumor Necrosis Factor-alpha / pharmacology*
  • Vascular Resistance / drug effects
  • Vasoconstrictor Agents / pharmacology
  • Vasodilation / drug effects*

Substances

  • Oxidants
  • Prostaglandin Endoperoxides, Synthetic
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • Vasoconstrictor Agents
  • Nitroprusside
  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • Superoxide Dismutase
  • Acetylcholine